Status:
COMPLETED
A Study of CT-868 in Type 1 Diabetes Mellitus
Lead Sponsor:
Carmot Therapeutics, Inc.
Conditions:
Overweight
Obese
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will b...
Eligibility Criteria
Inclusion
- Male or female, 18 years of age or older at the time of signing informed consent
- Have a documented clinical diagnosis of T1DM greater than or equal to 1 year before the Screening Visit
- Body mass index greater than or equal to27.0 kg/m2
- Hemoglobin A1c (HbA1c) level between 7.0% and 10.0%, inclusive, at the Screening Visit
Exclusion
- Diagnosis of Type 2 diabetes mellitus (T2DM) or any other types of diabetes, except T1DM
- Experienced diabetic ketoacidosis (DKA) within 3 months prior to the Screening Visit
- Experienced severe hypoglycemia (Level 3 as defined in the ADA Standards of Medical Care in Diabetes (ADA 2022) within 3 months prior to the Screening Visit
Key Trial Info
Start Date :
October 19 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 9 2025
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT06062069
Start Date
October 19 2023
End Date
July 9 2025
Last Update
July 17 2025
Active Locations (22)
Enter a location and click search to find clinical trials sorted by distance.
1
John Muir Physician Network Clinical Research Center
Concord, California, United States, 94520
2
Headlands Research- AMCR
Escondido, California, United States, 92025
3
University of Colorado - Barbara Davis Center for Diabetes
Aurora, Colorado, United States, 80045
4
Denver Endocrinology Diabetes and Thyroid Center
Englewood, Colorado, United States, 80113